As other Covid drugs grab headlines, this Bay Area company picks its spot to defeat virus

With a partnership with GlaxoSmithKline landing a Covid-fighting antibody drug in an ongoing late-stage clinical trial, the company Tuesday filed a "shelf registration" to sell $300 million in stock.

Click to view original post